If you cap insulin at $35 a month, people with type 2 diabetes stick to treatment, study finds
A new study found that capping monthly spending on insulin at $35 has led to increased treatment adherence and improved blood sugar levels among people with type 2 diabetes. The study analyzed records of 4.8 million people before and after the spending limit was implemented, showing significant reductions in out-of-pocket spending and increased insulin use.
Researchers have found that capping monthly spending on insulin at $35 has improved treatment outcomes for people with type 2 diabetes. The study, published in JAMA Internal Medicine, analyzed records of 4.8 million people before and after the spending limit was implemented. Out-of-pocket spending on insulin fell significantly, while insulin use increased. Blood sugar levels also improved, but there was a small increase in severe hypoglycemia events. The spending limit was introduced in response to a tripling of insulin prices from 2002 to 2013. The study's findings suggest that capping insulin costs can lead to better health outcomes for people with type 2 diabetes. The researchers noted that their results were clearer than those from some state programs, which have also implemented insulin cost caps.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.